 |
Octreotide |
|---|---|
| Trade Name | Sandostatin Lar |
| Orphan Indication | Severe diarrhea and flushing associated with malignant carcinoid tumors |
| USA Market Approval | USA |
| USA Designation Date | 1998-08-24 00:00:00 |
| Sponsor | Novartis Pharmaceuticals Corporation;59 Route 10;East Hanover, New Jersey, 07936 |
